MariMed Inc. (MRMD) Fair Value 2026

MRMD · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.8 /10

32 fundamental signals · 3 models active

Value Trap Risk

WARN (54/100)

Quick Summary — As of 2026-08-27, MariMed Inc. (MRMD) trades at $0.09, versus a $0.24 median fair value across its 3 active models — 162.8% above the current price. QOC: 6.8/10. Value Trap Risk: 54/100 (WARN). 3/13 models active.

Key Facts

Ticker
MRMD
Price
$0.09
Quality Score
6.8/10
Value Trap Risk
54/100
Models Active
3/13
Last Updated
Strength: PWERM suggests +267.9% upside with 33% confidence
Risk: Value Trap score of 54 suggests caution despite apparent undervaluation

Is MariMed Inc. (MRMD) Undervalued or Overvalued in 2026?

According to CirclFi’s 3-model valuation engine, MariMed Inc. (MRMD) appears undervalued as of : the median of 3 independent fair value estimates is $0.24, 162.8% above the current price of $0.09. Estimates range from $0.00 to $0.33. MRMD scores 6.8/10 on fundamental quality and 54/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. MRMD’s +162.8% gap is wider than that market norm, and the Drug Manufacturers - Specialty & Generic sector median is -1.4%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy MariMed Inc. Stock in 2026? →

What Fair Value Does Each Model Give MRMD?

3 Intrinsic Value Models vs. Current Price ($0.09)

Core Models (Unlocked)
Model Fair Value Upside
Scenario · High Conviction
 $0.00 -95.1%
Option-Based · Medium Conviction
 $0.33 +267.9%
Relative · Low Conviction
 $0.24 +162.8%

All Models Active

All 3 models are displayed above.

What Is MRMD's Fair Value Range?

Spread across 3 independent models · $0.00 to $0.33

CirclFi's 3 active models place MariMed Inc. (MRMD) between $0.00 and $0.33 per share, a spread of 138% of the median. The median of that range — $0.24 — is the fair value CirclFi publishes for MRMD, against a current price of $0.09.

Low · First ChicagoHigh · PWERM
$0.00median $0.24$0.33
Where the range comes from
Most bearish modelFirst Chicago$0.00
Most bullish modelPWERM$0.33
Model agreement2 bullish · 1 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for MRMD. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on MRMD, not a CirclFi price target. How each model works →

What Is MariMed Inc. (MRMD) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, MariMed Inc.'s intrinsic value is estimated at a median fair value of $0.24. While the stock appears modestly undervalued at $0.09 (implied upside of +162.8%), our analysis suggests a thinner margin of safety across 2 of 3 bullish models. Notably, PWERM sees the most upside at +267.9% (fair value: $0.33), while First Chicago is the most conservative at -95.1% ($0.00). The spread between these extremes — +362.9% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About MRMD?

3 of 13 models are currently active for MRMD. Of these, 2 models suggest upside while 1 model suggests overvaluation. Taken together, their median fair value for MRMD is $0.24 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does MRMD Rank in Drug Manufacturers - Specialty & Generic?

Among 110 Drug Manufacturers - Specialty & Generic stocks, MRMD ranks #35 by Quality of Company score. CirclFi's QOC score of 6.8/10 evaluates 32 fundamental signals. A score of 6.8 indicates above-average quality.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

MariMed Inc.'s positioning within the Drug Manufacturers - Specialty & Generic segment means that biosimilar competition timeline plays an outsized role in fundamental analysis. The sector's unique characteristics — including regulatory pathway clarity — shape both the opportunity set and risk profile.

Is MRMD a Value Trap?

CirclFi's Value Trap algorithm assigns MRMD a score of 54/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

3 of 13 models are active for MariMed Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, MariMed Inc. earns a quality score of 6.8/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.

The gap between the most bullish and bearish model spans +362.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every MRMD valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across MRMD's 3 active models, average confidence is 32%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy MariMed Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

BHCBausch Health Companies Inc.QOC 6.8ANIKAnika Therapeutics, Inc.QOC 6.8HROWHarrow, Inc.QOC 7.0TEVATeva Pharmaceutical Industries LimitedQOC 6.7TAKTakeda Pharmaceutical Company LimitedQOC 7.0AKBAAkebia Therapeutics, Inc.QOC 6.6PRGOPerrigo Company plcQOC 5.9CPHIChina Pharma Holdings, Inc.QOC 4.6ELTPElite Pharmaceuticals, Inc.QOC 8.8UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: BHC · ANIK · HROW · TEVA · TAK · AKBA · PRGO · CPHI · ELTP · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to MRMD?

7 companies across all industries closest to MRMD’s Quality of Company score of 6.8/10.

PIIPolaris Inc.QOC 6.8OMCOmnicom Group Inc.QOC 6.8SNAPSnap Inc.QOC 6.8DDominion Energy, Inc.QOC 6.8OCSLOaktree Specialty Lending CorporationQOC 6.8ARENThe Arena Group Holdings, Inc.QOC 6.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: PII · OMC · SNAP · D · OCSL · AREN · NVDA

Where Does MRMD Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

MRMD is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About MariMed Inc.’s Valuation?

What is MariMed Inc.'s intrinsic value in 2026?

CirclFi puts MariMed Inc. (MRMD)'s intrinsic value at $0.24 — the median of 3 independent model estimates as of 2026-08-27, ranging from $0.00 to $0.33. The Quality of Company score is 6.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is MRMD overvalued or undervalued right now?

At $0.09, 2 of 3 active models suggest MRMD may be undervalued, while 1 indicate potential overvaluation. The median of all 3 fair value estimates is $0.24, 162.8% above the current price of $0.09 — a consensus view that MRMD is undervalued. The assessment depends on which methodology best fits MariMed Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 6.8 mean for MRMD?

MariMed Inc.'s QOC of 6.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on MRMD?

CirclFi analyzes MRMD with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 3 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on MRMD?

Of the 3 models currently active on MRMD, PWERM is the most bullish at $0.33 per share, and First Chicago is the most bearish at $0.00. CirclFi's published fair value for MRMD is the median of that range, $0.24, not either extreme. The gap between the two ends equals 138% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is MRMD a value trap in 2026?

MariMed Inc.'s Value Trap score is 54/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries.

Cite this analysis — “According to CirclFi’s 3-model valuation engine, MariMed Inc. (MRMD) has a median fair value of $0.24 — 162.8% above the current price of $0.09 — as of 2026-08-27.” Source: circlfi.com/stock/MRMD/ · Methodology
Primary sources for this MRMD valuation
  • Financial statements: MariMed Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001522767) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for MRMD as of ; valuations recomputed .